Highlights
Recent real-world data confirms that elacestrant, the first-in-class oral selective estrogen receptor degrader (SERD), provides a clinically meaningful median time to next treatment (mTTNT) of 7.9 months in patients with ESR1-mutated metastatic breast cancer (mBC).
The efficacy was particularly pronounced in patients with no prior fulvestrant exposure, reaching a mTTNT of 12.9 months, suggesting a significant advantage in earlier endocrine sequencing.